Monoclonal antibodies (Formulary)

BENRALIZUMAB

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Solution for injection pre-filled syringe and pre-filled pens 30mg/mL (hospital use only)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

DUPILUMAB

Important: Therapy notes

MHRA advice: Dupilumab (Dupixent): risk of ocular adverse reactions and need for prompt management(November 2022) (www.gov.uk).

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled syringe 200mg, 300mg (specialist use only)

Dosage:

As per SMC 2317.
Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled pen 200mg, 300mg (specialist use only)

Dosage:

As per SMC 2317.
Homecare is the preferred option - contact nhsh.homecare@nhs.scot

MEPOLIZUMAB

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Solution for injection vials, pre-filled syringes and pre-filled pens 100mg (hospital use only)

Dosage:

Homecare is the preferred option - contact nhsh.homecare@nhs.scot

OMALIZUMAB

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled syringe 75mg/0·5mL, 150mg/mL (hospital use only)

Dosage:

By subcutaneous injection, adults and children over 6 years, according to immunoglobin E concentration and body-weight, refer to SPC.

TEZEPELUMAB

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Solution for injection in pre-filled syringe 210mg/1.91mL (110mg/mL) (specialist initiation only)

Dosage:

See SMC advice 2541.

Homecare is the preferred option - contact nhsh.homecare@nhs.scot.

Important: Formulation and dosage details

Formulation:

Solution for pre-filled pen 210mg/1.91ml (110mg/mL) (specialist initiation only)

Dosage:

See SMC advice 2541.

Homecare is the preferred option - contact nhsh.homecare@nhs.scot.

Editorial Information

Document Id: F359